CyageniCyagen
HomeAI Assistant
Toolbox
Databases
Resources
About Us
AI Tools
RNA Splicer
ASO Designer
Pathogenicity Predictor
Bioinfo Tools
Sequence Viewer
Mutation Direct
Antibody Discovery
Target Insights
Computational Analysis
Databases
Gene Database
Disease Database
Model Database
Mutation Database
Learn
Learning Center
Explore
iCyagen
Cyagen
OriCellTM
AbSeekTM
Contact
Contact Us
EN
中文
Hypercholesterolemia, Familial, 3 (FHCL3)
Alias:
Hypercholesterolemia, Autosomal Dominant, 3
|
Hypercholesterolemia
|
Hchola3
|
Fhcl3
|
Ldl - [low Density Lipoprotein} Hyperlipoproteinemia
|
Low-Density-Lipoprotein-Type Hyperlipoproteinemia
|
Low-Density-Lipoid-Type Hyperlipoproteinemia
|
Hypercholesterolaemia, Unspecified
|
Increased Low Density Lipoprotein
|
Essential Hypercholesterolaemia
|
Primary Hypercholesterolaemia
|
Low-Density-Lipoprotein-Type
|
Pure Hypercholesterolaemia
|
Pure Hypercholesterinaemia
|
Essential Cholesterolaemia
|
Group a Hyperlipidaemia
|
Hypercholesterolaemia
|
Increased Cholesterol
|
Group a Hyperlipemia
|
High Cholesterol
|
Cholesterolaemia
|
Fh3
Basic Information
Medical Symptom
Gene & Mutation
Related Drugs
Disease Model
References Literature
Familial hypercholesterolemia-3 (FHCL3) is an autosomal dominant disorder characterized by elevated low-density lipoprotein (LDL) cholesterol levels, leading to xanthelasma, xanthomas, accelerated atherosclerosis, and increased risk of premature coronary heart disease. It is a genetic disorder with high cholesterol levels, particularly high LDL levels, and early cardiovascular disease. FHCL3 is associated with a selective increase in LDL particles in plasma, resulting in tendon and skin xanthomas, arcus corneae, and coronary artery disease. The disorder is inherited in an autosomal dominant manner. Varret et al. (1999) described a French family with hypercholesterolemia, while Haddad et al. (1999) reported a Utah kindred with similar characteristics. FHCL3 is a form of hypercholesterolemia, a condition characterized by high cholesterol levels in the blood, which can lead to various health complications related to lipid metabolism.
Related ID:
MALACARDS: HYP272
|
OMIM: 603776
|
MESH: D006937
|
ICD11: 163750325
Basic Information
Inheritance
Age of Onset
Prevalence
Related Genes
Related Mouse Models
Reference
MALACARDS
AD
Autosomal dominant
Unknown
--
14
149
74
HYP272
Medical Symptom
Phenotype Information Associated with the Current Disease:
Categorization: Anatomical classification of the disease manifestations.
HPO Frequency/Orphanet Frequency: Indicates the probability of the manifestation occurring in the current disease, allowing sorting by probability.
HPO Source Accession: Links to HPO for detailed manifestation information.
Data Source: HPO, Orphanet
Gene & Mutation
Genes and Mutations Associated with the Current Disease:
Function: Primary biological roles of the genes.
Score: Indicates the strength of the association between the disease and the gene, with higher scores reflecting stronger associations.
Count: Number of mutations associated with the disease-gene pair. The number in parentheses represents the total data points linked to the same ClinVar ID. Clicking the number reveals mutation details.
Data Source: Clinvar
Related Drugs
Drugs Related to the Current Gene, Displaying CAS Number, Status and Phase.
Data Source: Clinical Trials
Related Mouse Models
Mouse Models Related to the Current Gene. Click on the model name to view detailed information.
Data Source: MGI, Cyagen
References Literature
Most Relevant Literature for the Current Gene, Filterable by Year, Article Type, and Sortable by Impact Factor.
Data Source: UniProt, PubMed
Cyagen
Home
Tools
Database
Resources
About Us
Email: icyagen-support@cyagen.com
Phone: +86 18620792549
Address: No.98, Xiangxue Road, Huangpu District, Guangzhou City
Follow us on social media
Contact us via LinkedIn
Link: https://www.linkedin.com/company/cyagen-biosciences
Copy
Contact us via YouTube
Link: https://www.youtube.com/@Cyagen
Copy
iCyagen
Copyright © 2024 Cyagen Biosciences. All Rights Reserved.
Privacy Policy
User Agreement
Back to top